PERSONALIZED APPROACH TO USING MIFEPRISTONE IN PATIENTS WITH UTERINE MYOMA
- Authors: Kareva E.N.1, Bekhbudova L.K.1, Gorenkova O.S.2, Samoilova T.E.3
-
Affiliations:
- Academician P.V. Sergeev Department of Molecular Pharmacology and Radiobiology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
- Moscow Regional Research Institute of Obstetrics and Gynecology
- N.I. Pirogov National Medical Surgical Center
- Issue: No 5 (2015)
- Pages: 61-65
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247410
- ID: 247410
Cite item
Abstract
Full Text
About the authors
Elena Nikolaevna Kareva
Academician P.V. Sergeev Department of Molecular Pharmacology and Radiobiology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: elenakareva@mail.ru
DM, Professor of Academician Moscow 117997, Ostrovitianov str. 1, Russia
Lamara Khanbalalovna Bekhbudova
Academician P.V. Sergeev Department of Molecular Pharmacology and Radiobiology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: Lamarabekh@gmail.com
Assistant of Department of Pharmacology Pediatric Faculty Moscow 117997, Ostrovitianov str. 1, Russia
Olga Sergeevna Gorenkova
Moscow Regional Research Institute of Obstetrics and Gynecology
Email: olga-gore@mail.ru
Candidate of Medical Science, gynecologist and endocrinologist Moscow 101000, Pokrovka str. 22a, Russia
Tatiana Evgen'evna Samoilova
N.I. Pirogov National Medical Surgical Center
Email: tesamoylova@mail.ru
MD, Professor of Department of Women’s Diseases and Reproductive Health Moscow 105203, Nizhnyaya Pervomayskaya str. 70, Russia
References
- Самойлова Т.Е. Медикаментозное лечение лейомиомы матки антигестагенами: возможности и перспективы. Охрана материнства и детства. 2012; 1-19: 102-9.
- Волков В.Г., Гусева Н.В., Горшкова И.А. Оптимизация консервативного лечения миомы матки антипрогестеронами и оценка влияния проводимой терапии на качество жизни женщин. Вестник новых медицинских технологий. 2011; 18(1): 92-3.
- Wilkens J., Chwalisz K., Han C., Walker J., Cameron I.T., Ingamells S. et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J. Clin. Endocrinol. Metab. 2008; 93(12): 4664-71.
- Rabe T., Ahrendt H.J., Albring C., Bitzer J., Bouchard P., Cirkel U. et al. Ulipristal acetate for symptomatic uterine fibroids and myoma-related hypermenorrhea. J. Reproduktionsmed. Endokrinol. 2013; 10(1): 82-101.
- Карева Е.Н. Мифепристон и миома матки. Фарматека. 2010; 14: 18-30.
- Патент на изобретение № 2312354, РФ. Способ диагностики эстроген- и прогестеронзависимой патологии гениталий. Карева Е.Н., Гаспарян Н.Д., Горенкова О.С., Маняхина А.Е. Заявлено 7 июля 2006, опубл. 10 декабря 2007. [
- Klein S.L., Roberts C.W. Sex hormones and immunity to infection. Berlin, Heidelberg: Springer-Verlag; 2010. 319 p.
- Карева Е.Н., Ганковская Л.В. Половые стероиды и иммунитет. Российский иммунологический журнал. 2012; 6(1): 3-13.
- Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008; 3(6): 1101-8.
- Esteve J.L., Acosta R., Pérez Y., Rodriguez B., Seigler I., Sanchez C., Tomasi G. Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial. Int. J. Womens Health. 2013; 5: 361-9.
- Engman M., Granberg S., Williams A.R., Meng C.X., Lalitkumar P.G., Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum. Reprod. 2009; 24(8): 1870-9.
- Djebli N., Fabre D., Boulenc X., Fabre G., Sultan E., Hurbin F. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics. Drug Metab. Dispos. 2015; 43(4): 510-22.